Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/77314
DC FieldValueLanguage
dc.contributor.authordel Amo, Juliaen_US
dc.contributor.authorPolo, Rosaen_US
dc.contributor.authorMoreno, Santiagoen_US
dc.contributor.authorDíaz, Asunciónen_US
dc.contributor.authorMartínez, Estebanen_US
dc.contributor.authorArribas, José Ramónen_US
dc.contributor.authorJarrín, Inmaen_US
dc.contributor.authorHernán, Miguel A.en_US
dc.contributor.authorPérez Arellano, José Luisen_US
dc.date.accessioned2021-01-25T15:03:48Z-
dc.date.available2021-01-25T15:03:48Z-
dc.date.issued2020en_US
dc.identifier.issn0003-4819en_US
dc.identifier.urihttp://hdl.handle.net/10553/77314-
dc.description.abstractBackground: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations. Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. Participants: 77 590 HIV-positive persons receiving ART. Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction–confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. Limitation: Residual confounding by comorbid conditions cannot be completely excluded. Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. Primary Funding Source: Instituto de Salud Carlos III and National Institutes of Health.en_US
dc.languageengen_US
dc.relation.ispartofAnnals of internal medicineen_US
dc.sourceAnnals of internal medicine [ISSN 0003-4819], v. 173 (7)en_US
dc.subject3202 Epidemologiaen_US
dc.titleIncidence and severity of COVID-19 in HIV-Positive persons receiving antiretroviral therapyen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.7326/M20-3689en_US
dc.identifier.issue7-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.identifier.ulpgcNoen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr3,839
dc.description.jcr25,391
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Trypanosomosis, Resistencia a Antibióticos y Medicina Animal-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2936-8242-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNamePérez Arellano, José Luis-
Appears in Collections:Artículos
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.